ADT impacts mood of patients with prostate cancer, as perceived by partners
the ONA take:
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer and those negative effects are concurrently observed by their partners, according to a new study published online ahead of print in the journal Psycho-Oncology.
For the study, researchers from Mount Allison University in Sackville, Canada, and the University of British Columbia in Vancouver, Canada, sought to assess the relationship between androgen deprivation therapy and the mood of patients with prostate cancer and their partners.
Researchers enrolled 295 patients and 84 partners. Participants completed an online survey evaluating the patients' current mood and mood prior to therapy, relationship adjustment, and sexual function. Results were compared with that of men who received non-hormonal treatments. Results showed that 82 patients currently treated with androgen deprivation therapy reported worsened mood compared with the 213 not on hormonal therapy. Researchers found that the 42 partners of patients on hormonal therapy reported declines in the patient's mood, but to a greater extent that the patient.
"The psychological changes related to ADT can impact relationships and affect the quality of life of both PCa patients and partners," the authors conclude. "Patients and their partners are likely to benefit from being well informed about the psychological effects of androgen deprivation on men beginning ADT."
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|